Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 7% Improvement Relative Risk Holt et al. NCT04330599 COVIDENCE UK Zinc Prophylaxis Does zinc reduce COVID-19 infections? Prospective study of 15,227 patients in the United Kingdom (May 2020 - Feb 2021) No significant difference in cases Holt et al., Thorax, doi:10.1136/thoraxjnl-2021-217487 Favors zinc Favors control
Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)
Holt et al., Thorax, doi:10.1136/thoraxjnl-2021-217487, COVIDENCE UK, NCT04330599 (history)
Holt et al., Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK), Thorax, doi:10.1136/thoraxjnl-2021-217487, COVIDENCE UK, NCT04330599
Mar 2021   Source   PDF  
  All Studies   Meta
Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistical significance was not reached for any of these. Except for vitamin D, the results for treatments we follow were only adjusted for age, sex, duration of participation, and test frequency. NCT04330599 (history). COVIDENCE UK. This study is excluded in the after exclusion results of meta analysis: significant unadjusted confounding possible.
risk of case, 6.8% lower, RR 0.93, p = 0.77, treatment 21 of 750 (2.8%), control 425 of 14,477 (2.9%), NNT 737, adjusted per study, odds ratio converted to relative risk, minimally adjusted, group sizes approximated.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Holt et al., 30 Mar 2021, prospective, United Kingdom, peer-reviewed, 34 authors, study period 1 May, 2020 - 5 February, 2021, trial NCT04330599 (history) (COVIDENCE UK).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Respiratory infection Risk factors for developing COVID-­19: a population-­ based longitudinal study (COVIDENCE UK) Hayley Holt,1 Mohammad Talaei ‍ ‍,1 Matthew Greenig,1 Dominik Zenner,1 Jane Symons,2 Clare Relton,1 Katherine S Young,3 Molly R Davies,3 Katherine N Thompson,3 Jed Ashman,1 Sultan Saeed Rajpoot,1 Ahmed Ali Kayyale,1 Sarah El Rifai ‍ ‍,1 Philippa J Lloyd ‍ ‍,1 David Jolliffe,1 Olivia Timmis,1 Sarah Finer,1 Stamatina Iliodromiti,1 Alec Miners,4 Nicholas S Hopkinson ‍ ‍,5 Bodrul Alam,6 Graham Lloyd-­Jones ‍ ‍,7 Thomas Dietrich,8 Iain Chapple,8 Paul E Pfeffer ‍ ‍,1 David McCoy,1 Gwyneth Davies,9 Ronan A Lyons,9 Christopher Griffiths,1 Frank Kee ‍ ‍,10 Aziz Sheikh,11 Gerome Breen,3 Seif O Shaheen,1 Adrian R Martineau ‍ ‍1 ►► Additional supplemental material is published online only. To view, please visit the journal online (http://d​ x.​doi.​ org/1​ 0.​1136/t​ horaxjnl-​2021-​ 217487). For numbered affiliations see end of article. Correspondence to Professor Adrian R Martineau, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK; ​a.​martineau@q​ mul.​ac.​uk HH, MT, SOS and ARM contributed equally. Received 19 April 2021 Accepted 9 September 2021 © Author(s) (or their employer(s)) 2021. No commercial re-­use. See rights and permissions. Published by BMJ. To cite: Holt H, Talaei M, Greenig M, et al. Thorax Epub ahead of print: [please include Day Month Year]. doi:10.1136/ thoraxjnl-2021-217487 ABSTRACT Background Risk factors for severe COVID-­19 include older age, male sex, obesity, black or Asian ethnicity and underlying medical conditions. Whether these factors also influence susceptibility to developing COVID-­19 is uncertain. Methods We undertook a prospective, population-­ based cohort study (COVIDENCE UK) from 1 May 2020 to 5 February 2021. Baseline information on potential risk factors was captured by an online questionnaire. Monthly follow-­up questionnaires captured incident COVID-­19. We used logistic regression models to estimate multivariable-­adjusted ORs (aORs) for associations between potential risk factors and odds of COVID-­19. Results We recorded 446 incident cases of COVID-­19 in 15 227 participants (2.9%). Increased odds of developing COVID-­19 were independently associated with Asian/Asian British versus white ethnicity (aOR 2.28, 95% CI 1.33 to 3.91), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11 to 1.43), any versus no visits to/from other households in previous week (aOR 1.31, 1.06 to 1.62), number of visits to indoor public places (aOR per extra visit per week 1.05, 1.02 to 1.09), frontline occupation excluding health/social care versus no frontline occupation (aOR 1.49, 1.12 to 1.98) and raised body mass index (BMI) (aOR 1.50 (1.19 to 1.89) for BMI 25.0–30.0 kg/m2 and 1.39 (1.06 to 1.84) for BMI >30.0 kg/m2 versus BMI <25.0 kg/m2). Atopic disease was independently associated with decreased odds (aOR 0.75, 0.59 to 0.97). No independent associations were seen for age, sex, other medical conditions, diet or micronutrient supplement use. Conclusions After rigorous adjustment for factors influencing exposure to SARS-­CoV-­2, Asian/Asian British ethnicity and raised BMI were associated with increased odds of developing COVID-­19, while atopic disease was associated with decreased odds. Trial registration number C ​ linicalTrials.​gov Registry (NCT04330599). Key messages What is the key question? ►► How..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop